Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465361 | 0.88 | HTR2A (0.42) | HTR2ATAAR1ALDH1A1SLC6A4GAA | |
| SCHEMBL3465279 | 0.88 | HTR2A (0.42) | HTR2ATAAR1ALDH1A1SLC6A4GAA | |
| SCHEMBL28548526 | 0.86 | HTR2A (0.41) | HTR2ATAAR1ALDH1A1GAANFKB1 | |
| SCHEMBL14032377 | 0.83 | ACHE (0.51) | ALDH1A1SLC6A4GAANFKB1 | |
| SCHEMBL8217961 | 0.81 | HTR2A (0.46) | HTR2ATAAR1 | |
| SCHEMBL30753311 | 0.81 | HTR2A (0.46) | HTR2ATAAR1 | |
| SCHEMBL27358818 | 0.81 | HTR2A (0.46) | HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL5117534 | 0.81 | ACHE (0.50) | ALDH1A1SLC6A4GAA | |
| SCHEMBL15052824 | 0.81 | HTR2A (0.46) | HTR2ATAAR1 | |
| SCHEMBL28346722 | 0.79 | HTR2A (0.40) | HTR2ATAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2655371-B1 | PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-8546442-B2 | Pyrazolopiperidine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | HTR2A 3250/4885TAAR1 186/4885ALDH1A1 523/4885 |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | HTR2A 2444/4885TAAR1 276/4885ALDH1A1 719/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | HTR2A 3700/4885TAAR1 793/4885ALDH1A1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.